» Articles » PMID: 16876135

Alteration in Kinase Activity but Not in Protein Levels of Protein Kinase B and Glycogen Synthase Kinase-3beta in Ventral Prefrontal Cortex of Depressed Suicide Victims

Overview
Journal Biol Psychiatry
Publisher Elsevier
Specialty Psychiatry
Date 2006 Aug 1
PMID 16876135
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Past studies in the neurobiology of suicide have reported alterations in serotonin and downstream effectors, such as Akt/protein kinase B. In this study, we aimed to examine possible abnormality in the Akt/glycogen synthase kinase-3beta (GSK-3beta) axis of depressed suicide victims' brains.

Methods: Twenty suicide victims and 20 drug-free non-suicide subjects were included for a postmortem study. The ventral prefrontal cortex area (BA'11) was used, and antemortem diagnoses of major depression disorder (MDD) (DSM-IV) were made from Institution's records. The protein levels of GSK-3alpha/beta and Akt-1 were assayed with the Western blot method, and the kinase activity of Akt and GSK-3alpha/beta were determined by phosphorylation of specific substrates.

Results: There was no change either in GSK-3alpha/beta and Akt-1 protein levels or in lithium-inhibitable total GSK-3alpha/beta enzyme activity of the ventral prefrontal cortex. The enzyme activity of Akt decreased significantly [analysis of variance (ANOVA): F(3,36)=5.372; p= .003], whereas GSK-3beta activity increased significantly [ANOVA: F(3,36)=8.567; p= .002] in depressed suicide victims and non-suicide subjects but not in non-depressed suicide victims.

Conclusions: This study indicated that the activity rather than the protein levels of Akt and GSK-3beta was altered. The alteration was associated with MDD rather than with suicide per se.

Citing Articles

Behavioral Test Scores Could Be Linked to the Protein Expression Values of p62 and GLAST in the Brains of Mice with Neuropsychiatric Disorder-Related Behaviors.

Ikeda Y, Nakashima M, Yoshikawa S, Taniguchi K, Suga N, Matsuda S Biology (Basel). 2025; 13(12.

PMID: 39765706 PMC: 11672909. DOI: 10.3390/biology13121039.


NRF2, KEAP1 and GSK-3 levels in autism spectrum disorder: a case control study.

Subasi Turgut F, Karadag M, Taysi S, Hangul Z, Gokcen C Int J Dev Disabil. 2024; 70(8):1441-1451.

PMID: 39713511 PMC: 11660297. DOI: 10.1080/20473869.2023.2185959.


Identifying the differentially expressed peripheral blood microRNAs in psychiatric disorders: a systematic review and meta-analysis.

Liu X, Dong L, Jiang Z, Song M, Yan P Front Psychiatry. 2024; 15:1390366.

PMID: 38827444 PMC: 11140110. DOI: 10.3389/fpsyt.2024.1390366.


New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.

Bortolozzi A, Fico G, Berk M, Solmi M, Fornaro M, Quevedo J Pharmacol Rev. 2024; 76(3):323-357.

PMID: 38697859 PMC: 11068842. DOI: 10.1124/pharmrev.120.000007.


Marked alteration of phosphoinositide signaling-associated molecules in postmortem prefrontal cortex with bipolar disorder.

Hino M, Kunii Y, Shishido R, Nagaoka A, Matsumoto J, Akatsu H Neuropsychopharmacol Rep. 2024; 44(1):121-128.

PMID: 38253804 PMC: 10932789. DOI: 10.1002/npr2.12409.